Capillary sprout endothelial cells exhibit a CD36low phenotype: Regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling

American Journal of Pathology

Volumn 173, Issue 4, 2008, Pages 1220-1228

  Anderson, Christopher R ^a   Hastings, Nicole E ^a   Blackman, Brett R ^a   Price, Richard J ^a,b  

^a University of Virginia   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD36 ANTIGEN; LECTIN; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SHEAR STRESS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 53149086261     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.071194     Document Type: Article

References (43)

1. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9:653-660
2. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571
3. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537
4. Anderson CR, Ponce AM, Price RJ: Absence of OX-43 antigen expression in invasive capillary sprouts: identification of a capillary sprout-specific endothelial phenotype. Am J Physiol 2004, 286:H346-H353
5. Robinson AP, White TM, Mason DW: MRC OX-43: a monoclonal antibody which reacts with all vascular endothelium in the rat except that of brain capillaries. Immunology 1986, 57:231-237
6. Asch AS, Barnwell J, Silverstein RL, Nachman RL: Isolation of the thrombospondin membrane receptor. J Clin Invest 1987, 79:1054-1061
7. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
8. Benjamin LE: The controls of microvascular survival. Cancer Metastasis Rev 2000, 19:75-81
9. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990, 87:6624 -6628
10. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993, 122:497-511
11. Vogel T, Guo NH, Krutzsch HC, Blake DA, Hartman J, Mendelovitz S, Panet A, Roberts DD: Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993, 53:74-84
12. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999, 100:1423-1431
13. Volpert OV, Lawler J, Bouck NP: A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998, 95:6343-6348
14. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG: Thrombospondins and tumor angiogenesis. Trends Mol Med 2001, 7:401-407
15. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, Lange-Asschenfeldt B, Yano K, Hawighorst T, Iruela-Arispe L, Detmar M: Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000, 19:3272-3282
16. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC: Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002, 98:682-689
17. Westphal JR: Technology evaluation: ABT-510. Abbott Curr Opin Mol Ther 2004, 6:451-457
18. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138:707-717
19. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000, 6:41-48
20. Guo N, Krutzsch HC, Inman JK, Roberts DD: Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997, 57:1735-1742
21. Norrby KA, Jakobsson, Sorbo J: Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986, 52:195-206
22. Ponce AM, Price RJ: Angiogenic stimulus determines the positioning of pericytes within capillary sprouts in vivo. Microvasc Res 2003, 65:45-48
23. Garcia-Cardeña G, Comander J, Anderson KR, Blackman BR, Gimbrone MA: Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001, 98:4478-4485
24. Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, García-Cardeña G, Gimbrone MA: Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci USA 2004, 101:14871-14876
25. Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR: Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes proinflammatory priming. Am J Physiol 2007, 93:C1824-C1833
26. Mader JS, Smyth D, Marshall J, Hoskin DW: Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am J Pathol 2006, 169:1753-1766
27. Chai J, Jones MK, Tarnawski AS: Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis. FASEB J 2004, 18:1264-1266
28. Williams CK, Li JL, Murga M, Harris AL, Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006, 107:931-939
29. Tressel SL, Huang RP, Tomsen N, Jo H: Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism. Arterioscler Thromb Vasc Biol 2007, 27:2150-2156
30. Petrik JJ, Gentry PA, Feige JJ, LaMarre J: Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod 2002, 67:1522-1531
31. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R: Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005, 102:2934-2939
32. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP: Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002, 8:349-357
33. DiPietro LA, Nebgen DR, Polverini PJ: Down-regulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res 1994, 31:178-185
34. Chen D, Asahara T, Krasinski K, Witzenbichler B, Yang J, Magner M, Kearney M, Frazier WA, Isner JM, Andrés V: Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon-injured rat carotid artery. Circulation 1999, 100:849-854
35. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98:12485-12490
36. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994, 152:4149-4156
37. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994, 180:1141-1146
38. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027
39. Taraboletti G, Roberts D, Liotta LA, Giavazzi R: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990, 111:765-772
40. Bagavandoss P, Wilks JW: Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 1990, 170:867-872
41. Calzada MJ, Zhou L, Sipes JM, Zhang J, Krutzsch HC, Iruela-Arispe ML, Annis DS, Mosher DF, Roberts DD: Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res 2004, 94:462-470
42. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR: Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005, 168:643-653
43. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, Zeng L, Yuan X, Wang N, Chien S, Forman BM, Shyy JY: Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 2004, 110:1128-1133